PMID- 38010279
OWN - NLM
STAT- MEDLINE
DCOM- 20240401
LR  - 20240401
IS  - 1540-0514 (Electronic)
IS  - 1073-2322 (Linking)
VI  - 61
IP  - 3
DP  - 2024 Mar 1
TI  - SOLUBLE GUANYLATE CYCLASE STIMULATORS IN HEART FAILURE WITH PRESERVED EJECTION 
      FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
PG  - 333-339
LID - 10.1097/SHK.0000000000002277 [doi]
AB  - Aims: We conducted a systemic review and meta-analysis to evaluate the 
      therapeutic efficacy and safety of soluble guanylate cyclase (sGC) stimulators in 
      patients with heart failure with preserved ejection fraction (HFpEF). Methods : 
      We systematically searched PubMed, Embase, and Cochrane Library databases for 
      original randomized controlled trials comparing sGC stimulators with placebo in 
      HFpEF patients. A random-effects model was applied to evaluate the mortality, 
      quality of life, and drug-related adverse events. This meta-analysis is 
      registered in PROSPERO under the number CRD42023457382. Results : We included 
      five studies involving 1,600 HFpEF patients. Comprehensively, the combined risk 
      ratio (RR) for mortality was not significant (RR [95% CI] = 1.44 [0.71 to 2.91], 
      P = 0.31). Furthermore, there were no statistically significant differences in 
      the Kansas City Cardiomyopathy Questionnaire results, including the clinical 
      summary score (weighted mean difference [WMD] [95% CI] =0.32 [-7.38 to 8.02], P = 
      0.94) and the overall summary score (WMD [95% CI] = -0.87 [-8.87 to 7.14], P = 
      0.83). Similarly, there was no significant improvement in the 6-minute walk 
      distance (WMD [95% CI] = -6.22 [-18.56 to 6.12], P = 0.32). In addition, 
      drug-related adverse events were more common in patients treated with sGC 
      stimulators (RR [95% CI] = 1.63 [1.25-2.14], P < 0.05). Conclusion : Oral sGC 
      stimulators do not significantly improve mortality outcomes, functional capacity, 
      and quality of life in HFpEF patients but are associated with increased 
      drug-related adverse events. Therefore, we should consider using sGC stimulators 
      in HFpEF patients carefully.
CI  - Copyright (c) 2023 by the Shock Society.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Critical Care Medicine, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Zang, Bin
AU  - Zang B
AD  - Department of Critical Care Medicine, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Emergency, The Fourth Affiliated Hospital of China Medical 
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231122
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
RN  - EC 4.6.1.2 (Soluble Guanylyl Cyclase)
RN  - 0 (Pyrimidines)
RN  - 0 (Vasodilator Agents)
SB  - IM
MH  - Humans
MH  - Soluble Guanylyl Cyclase/therapeutic use
MH  - *Heart Failure/drug therapy
MH  - Quality of Life
MH  - Stroke Volume
MH  - Pyrimidines/adverse effects
MH  - Vasodilator Agents/therapeutic use
COIS- The authors report no conflicts of interest.
EDAT- 2023/11/27 12:42
MHDA- 2024/04/01 06:43
CRDT- 2023/11/27 10:35
PHST- 2024/04/01 06:43 [medline]
PHST- 2023/11/27 12:42 [pubmed]
PHST- 2023/11/27 10:35 [entrez]
AID - 00024382-990000000-00335 [pii]
AID - 10.1097/SHK.0000000000002277 [doi]
PST - ppublish
SO  - Shock. 2024 Mar 1;61(3):333-339. doi: 10.1097/SHK.0000000000002277. Epub 2023 Nov 
      22.